Curie.Bio

During his drug development career, Ryan Sullivan has led or contributed to the development of several complex biologics - including antibodies, cytokines, vaccines, and cell therapies. He brings those insights to the team at Curie.Bio and works closely with our PortCo founders to design and build successful biologic therapies. "Biologics are inherently complex, and navigating the maze of their discovery and development even more so. Curie.Bio was created to streamline this journey for Founders, and being part of that mission is what inspires me every day." Learn more about how Ryan can help you design your drug here: https://lnkd.in/eCJNeRrx

Throughout Aron Jaffe’s career, he has been committed to advancing and leveraging bleeding-edge technologies to uncover new biological insights and unlock new therapeutic opportunities. At Curie.Bio, Aron helps our founders translate new biological insights and platform technologies into great therapeutics companies that can deliver life-changing medicines. Check out a few of the bleeding-edge scientific innovations led by Aron below. Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung: https://lnkd.in/eAEi-bcU A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte: https://lnkd.in/ezjfJy5Y A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels:  https://lnkd.in/eC55NcV6

A pharmacist by training, Antoine Henninot Ph.D’s background has enabled him to collaborate effectively across many disciplines integral to drug discovery and development. During his time at Takeda, Antoine established and led the peptide and bioconjugation team, overseeing multiple peptide drug discovery projects leveraging known hormones, or initiating campaigns for de novo ligands using various display technologies. Now, he’s lending his expertise to Curie.Bio founders to help them create best-in-class peptide-based therapies. Antoine shares more here. https://lnkd.in/ejGWG7if

🚀 Calling all Swiss #biotech founders! Curie.Bio is bringing its founder-focused model to #Switzerland as a proud sponsor of Bayer Co.Lab Connect – Basel alongside Bayer, Goodwin, Danforth Advisors, and Superlab Suisse. If you're building the next generation of therapeutics companies in Switzerland and want to break into the U.S. ecosystem, this is your opportunity. At Curie.Bio, we do more than invest—we help founders define, plan, and execute the drug discovery strategy that maximizes their chances of making impactful medicines. Our 80+ drug hunters and biotech operators serve as an extension of your team, helping you hit critical milestones on your path to the clinic. With over $1.2B raised, 500 vetted CROs, and a proven track record—like Forward Therapeutics, Inc. raising $50M for its Series A after just 18 months and $8M—we know how to build serious therapeutics companies efficiently. If you're a Swiss biotech founder looking to gain access to world-class R&D resources and expert guidance, this program is designed for you. 🔗 Apply here by March 30. https://lnkd.in/g5SDdvfS #FreeTheFounders #SwissBiotech 

“I joined Curie.Bio because I believe our model is uniquely suited to helping new companies grow. There’s a level of expertise here that’s hard for any individual company to replicate or access, and that’s often the difference between a good outcome and a great one.”    Curie.Bio CXO Ankit Mahadevia has co-founded nine biotech companies, serving them in every role from advisor, Board member, investor, to CEO. He is well-equipped to help founders take their ideas and execution from good to great. https://lnkd.in/eAtNtXQ5

Today, we celebrate those pioneering groundbreaking therapies for those living with a #raredisease, the majority of which still need new treatment options. This includes Curie.Bio co-pilot Andy Garner. While much of Andy's experience at Blueprint Medicines focused on novel cancer treatments, he was able to leverage his expertise in kinase drug discovery to lead the discovery of fidrisertib, an ALK2 inhibitor that is currently advancing in the clinic as a potential treatment for Fibrodysplasia Ossificans Progressiva (FOP), a rare, debilitating genetic disorder characterized by the progressive formation of bone in soft tissues. #RareDiseaseDay

What does it really take to turn a bold idea into a transformative medicine? The journey is anything but straightforward—that’s why we’re excited to welcome Kelly Moynihan to Curie.Bio as a co-pilot to support the founders of our portfolio companies. Kelly has seen firsthand how early, strategic decisions—like target selection, indication prioritization, and development strategy—shape a company’s trajectory and long-term success. With hands-on experience in starting companies and advancing drugs from bench to clinic, she’s passionate about helping founders navigate the complexities of drug development. Read more about Kelly here: https://lnkd.in/gWE6PFXr

“It is a daunting task designing an efficacious, potent, and selective drug, with the desired pharmacokinetic profile, without causing toxicity, in a dosing regime acceptable for patients.” As a co-pilot at Curie.Bio, Chris Smith FRSC leverages his deep experience in designing multiple clinical-stage molecules to help founders create molecules with the right profile to make an impact for patients. Chris shares more about his passion for drug design on our website. https://lnkd.in/eUawThGt 

At Curie.Bio, we celebrate creative scientists and drug hunters who push the boundaries of what’s possible in medicine. On this International Day of Women & Girls in Science, we’re reminded of the powerful contributions women have made to drug discovery and development—most notably Marie Curie. Her pioneering research on radioactivity, including the discovery of polonium and radium, laid the foundation for radiation oncology and changed how we treat cancer today. Learn more about her incredible legacy via The Nobel Prize: https://lnkd.in/eSMB82Xd #WomenInScience

During his 20+ years as a Research & Early Development Scientist at Roche, Christian Klein has contributed to the development of over 30 clinical-stage drug candidates, including four approved therapies that continue to change patients’ lives daily. Now as a CXO at Curie.Bio, Christian works closely with our founders to translate their innovative ideas into actionable drug discovery programs. “I joined Curie.Bio because I believe in the power of collaboration. Throughout my career, I have learned that the best ideas often emerge from a diverse group of experts coming together, and Curie.Bio embodies that philosophy.”   Learn more about Christian: https://lnkd.in/eYXrxC-w